Zobrazeno 1 - 10
of 1 336
pro vyhledávání: '"L. Talarico"'
Autor:
L. Talarico, R. Caniglia, A. Carosi, M. Lorenzoni, C. Greco, A. Padula, S. D’Antoni, D. Alberti, A. de Paoli, L. Casali, M. Ruocco, G. Tedaldi, C. Pedrazzoli, N. Mucci
Publikováno v:
The European Zoological Journal, Vol 90, Iss 1, Pp 470-486 (2023)
AbstractThe Salmo trutta species complex includes threatened or intensively managed taxa. Domestic-Atlantic strains are widely farmed and massively introduced into the wild to support fisheries, although such practices seriously threaten native popul
Externí odkaz:
https://doaj.org/article/6ef1f6019aa54bfbbb141a579b523293
Autor:
A. Byrne, L. Talarico
Publikováno v:
International Journal of Infectious Diseases, Vol 130, Iss , Pp S124-S125 (2023)
Intro: Antibodies play a critical role in protection and pathogenesis of dengue virus (DENV). In the presence of preexisting antibodies that bind but do not neutralize viral particles, virus-antibody immune complexes are internalized by Fcγ receptor
Externí odkaz:
https://doaj.org/article/72517ece1c154998934ec53f9d723a09
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 30, Iss 3, Pp 808-812 (2016)
Background Noninvasive methods of quantitating exercise tolerance in dogs with neuromuscular disease are needed both for clinical and research use. The 6‐minute walk test (6MWT) has been validated as a reliable test of exercise tolerance in dogs wi
Externí odkaz:
https://doaj.org/article/41cd03e8e6d449f99d1325fcbf213ef0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Thomas A. Lutz, Susan Swindells, Vasiliki Chounta, Christine L. Talarico, Jenny Huang, Lelanie van Zyl, Paul D Benn, William Spreen, Kati Vandermeulen, Kimberly Y. Smith, Herta Crauwels, Conn M. Harrington, Essack Mitha, Norma Porteiro, Susan L. Ford, Simon Vanveggel, Matthias Stoll, Kai S Hove, Rodica Van Solingen-Ristea, David A. Margolis, Alyssa Shon
Publikováno v:
AIDS (London, England)
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study, demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long-acting dosed every 4 weeks was noninferior at week (W) 48 to continuing three-drug dai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2e6b50ecd94d0bfad37aa24f4e93b88
http://europepmc.org/articles/PMC8711605
http://europepmc.org/articles/PMC8711605
Autor:
Veerle Van Eygen, David A. Margolis, Marty St. Clair, Jerry Jeffrey, Daniel R. Kuritzkes, Michael Aboud, Jan van Lunzen, Yongwei Wang, William Spreen, Christine L. Talarico, Mark Baker, Kati Vandermeulen, Amy Cutrell, Carlo Federico Perno, Jonathan M. Schapiro, David Dorey, Susan L. Ford, Herta Crauwels, C. Thomas White, Joseph W. Polli, Romina Quercia, Simon Vanveggel, Sterling Wu, Parul Patel
Publikováno v:
AIDS (London, England)
Current antiretroviral therapy (ART) consists of a combination of two or more oral agents from at least two drug classes, such as an integrase strand transfer inhibitor (INSTI) as well as one or two nucleoside reverse transcriptase inhibitors (NRTIs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8628b61e4e5a6408b1220516448bebf7
http://europepmc.org/articles/PMC8270504
http://europepmc.org/articles/PMC8270504
Autor:
M. Andreassi, C. Salvini, C. Bonechi, G. Tamasi, A. Magnani, C. Federici, L. Talarico, C. Rossi
Publikováno v:
Journal of Investigative Dermatology. 143:S186
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7276f79cb961275471d3a0e107506e3d
https://doi.org/10.1016/j.jid.2023.03.1098
https://doi.org/10.1016/j.jid.2023.03.1098
Autor:
Miguel García Deltoro, Veerle Van Eygen, Paul D Benn, Kimberly Y. Smith, Hans Jaeger, Parul Patel, Fritz Bredeek, Rodica Van Solingen-Ristea, Christine L. Talarico, William Spreen, Marie-Aude Khuong-Josses, Simon Vanveggel, Susan L. Ford, Gary Richmond, Edgar T. Overton, Giuliano Rizzardini, Krischan J Hudson, Amy Cutrell, Susan Swindells, Vasiliki Chounta, Jaime Andrade-Villanueva, Catherine Orrell, Herta Crauwels, David A. Margolis, Mark S. Shaefer, Firaya Nagimova, Yuanyuan Wang, Alexander Wong
Publikováno v:
The Lancet. 396:1994-2005
Phase 3 clinical studies showed non-inferiority of long-acting intramuscular cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important phase 2 results of every 8 weeks dosing, and supportive modelling, underpin furthe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba4e7fbadd20f255f1dfaee3cb18f5a3
https://doi.org/10.1016/s0140-6736(20)32666-0
https://doi.org/10.1016/s0140-6736(20)32666-0
Publikováno v:
In Antiviral Research 2000 46(1):A78-A78
Autor:
Babafemi O Taiwo, Darrell Tan, Parul Patel, Paula Teichner, Joseph Polli, Louise Garside, Ronald D’Amico, Christine L Talarico, Rodica Van Solingen-Ristea, Bryan Baugh, William Spreen, Michael Aboud, Matthew Bosse
Publikováno v:
Open Forum Infectious Diseases
Background Cabotegravir (CAB) plus rilpivirine (RPV) is the first complete long-acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. CAB+RPV LA dosed every 4 weeks (Q4W) or every 8 weeks (Q8W) de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55e32ab926029e2a2624c123148141e7
http://europepmc.org/articles/PMC8644679
http://europepmc.org/articles/PMC8644679